Bluebird’s Zynteglo Approval Kicks Off Commercial Operations

Beta-Thalassemia Gene Therapy’s List Price Is $2.8m

 
• By Mandy Jackson
  
business people stacking cogwheels in team
Bluebird already has assembled the provider, payer and patient support pieces of its commercial operations • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip